D-0136-2017 Class III Terminated

Recalled by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) — Rockford, IL

FDA drug recall D-0136-2017 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on Sep 28, 2016 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 16 month timepoint. The recall status is terminated (terminated Aug 28, 2018). Affected quantity: 46,472 unit dose blister cards (10 cards of 10 tablets each).

Recall details

Product Type
Drugs
Report Date
Nov 16, 2016
Initiation Date
Sep 28, 2016
Termination Date
Aug 28, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
46,472 unit dose blister cards (10 cards of 10 tablets each)

Product description

Clonazepam Tablets, USP, 1.0 mg, packaged in a 100- count unit dose box of 10 x 10 blister cards, Rx only, Manufactured by Mylan Pharmaceuticals Inc, Morgantown, WV, 26505, NDC 51079-882-20

Reason for recall

Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 16 month timepoint.

Distribution pattern

Nationwide

Code information

Lot#: 3061784, Exp 11/16; 3067656, Exp 12/16; 3074902, Exp 08/17

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0136-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0136-2017. Report a data issue: hello@regdatalab.com.